2
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
16
Prostatic Neoplasms
4
Neoplasms
4
Carcinoma, Intraductal, Noninfiltrating
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Precancerous Conditions
2
Peripheral Nervous System Diseases
2
Pain
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Cardiovascular Diseases
2
Breast Carcinoma In Situ
2
Arthralgia
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Radiation Injuries
1
Psoriasis
1
Polyps
1
Polycystic Ovary Syndrome
1
Pelvic Inflammatory Disease
1
Ovarian Neoplasms
1
Osteoarthritis
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Interventions
Fluorouracil
219
Leucovorin
202
Oxaliplatin
192
Irinotecan
150
Bevacizumab
110
Capecitabine
94
Cetuximab
90
Folfox protocol
54
Chemotherapy, Adjuvant
36
Panitumumab
30
Colonoscopy
30
pembrolizumab
23
Drug Therapy
23
Nivolumab
22
Magnetic Resonance Spectroscopy
22
Gemcitabine
21
Blood Specimen Collection
20
Radiotherapy
19
Floxuridine
19
Biopsy
19
Neoadjuvant Therapy
18
Laparoscopy
18
IFL protocol
18
Early Intervention, Educational
18
Celecoxib
18
Surveys and Questionnaires
17
Surgical Procedures, Operative
16
Immunohistochemistry
16
Exercise
16
trifluridine tipiracil drug combination
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Fatty Acids, Omega-3
×
Clear all
NCT03661047
2021-11-17
OMICC
Massachusetts General Hospital
Phase 2
Withdrawn
NCT02231203
2018-07-31
EMPIRE
Medical Center Alkmaar
Phase 4
Completed
44 enrolled